Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/11/2019 10:29 PST] Global Blood Therapeutics, Inc. (NASDAQ:GBT), Up By 100.00% ($40.00) From $40.000 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/27/2018 07:42 PST] GBT Expected to Trade Up After Bullish Patterns Develop
• [12/20/2018 09:55 PST] Global Blood Therapeutics, Inc. (NASDAQ:GBT), Down By 100.00% ($42.75) From $42.750 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [12/12/2018 08:59 PST] GBT Expected to Trade Down After Bearish Patterns Develop
• [12/03/2018 10:10 PST] GBT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.